NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Ascending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
31722-0962-60 | 31722-0962 | dronabinol | DRONABINOL | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Feb. 10, 2020 | In Use | |
35356-0853-06 | 35356-0853 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 11, 2015 | In Use | |
35356-0853-09 | 35356-0853 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 11, 2015 | In Use | |
35356-0853-10 | 35356-0853 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 27, 2007 | In Use | |
35356-0853-20 | 35356-0853 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 27, 2007 | In Use | |
35356-0853-30 | 35356-0853 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 27, 2007 | In Use | |
43598-0859-11 | 43598-0859 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 6, 2019 | In Use | |
43598-0948-11 | 43598-0948 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | July 1, 2020 | In Use | |
61703-0326-18 | 61703-0326 | Pamidronate Disodium | Pamidronate Disodium | 9.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Oct. 1, 2005 | In Use | ||
67457-0430-10 | 67457-0430 | Pamidronate Disodium | Pamidronate Disodium | 3.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Nov. 1, 2008 | In Use | ||
67457-0446-10 | 67457-0446 | Pamidronate Disodium | Pamidronate Disodium | 9.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Nov. 1, 2008 | In Use | ||
54868-5229-00 | 54868-5229 | Pegfilgrastim | Neulasta | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Feb. 23, 2006 | Dec. 31, 2011 | No Longer Used | ||
55513-0190-01 | 55513-0190 | Pegfilgrastim | Neulasta | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | April 1, 2002 | In Use | |
00024-5862-01 | 00024-5862 | Plerixafor | Mozobil | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Sept. 1, 2013 | In Use | |
00024-5150-10 | 00024-5150 | Rasburicase | Elitek | Ancillary Therapy | Metabolic Agent | Enzyme | July 12, 2002 | In Use | |||
00024-5151-75 | 00024-5151 | Rasburicase | Elitek | Ancillary Therapy | Metabolic Agent | Enzyme | June 1, 2006 | In Use | |||
57902-0860-03 | 57902-0860 | Samarium SM 153 Lexidronam | Quadramet | 50.0 mCi/mL | Ancillary Therapy | Radiopharmaceutical | Samarium Sm 153 | Intravenous | May 19, 1997 | In Use | |
50419-0002-33 | 50419-0002 | Sargramostim | Leukine | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Sept. 5, 1991 | Sept. 21, 2012 | No Longer Used | ||
50419-0050-14 | 50419-0050 | Sargramostim | Leukine | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | March 5, 1991 | Sept. 21, 2012 | No Longer Used | ||
50419-0050-30 | 50419-0050 | Sargramostim | Leukine | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | March 5, 1991 | Sept. 21, 2012 | No Longer Used | ||
54868-3188-00 | 54868-3188 | Sargramostim | Leukine | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Dec. 1, 1996 | June 30, 2012 | No Longer Used | ||
58468-0181-01 | 58468-0181 | Sargramostim | Leukine | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | March 15, 2010 | Dec. 31, 2013 | No Longer Used | ||
58468-0181-02 | 58468-0181 | Sargramostim | Leukine | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | March 15, 2010 | Dec. 31, 2013 | No Longer Used | ||
69468-0151-04 | 69468-0151 | Uridine Triacetate | Vistogard | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | March 1, 2016 | In Use | |
69468-0151-10 | 69468-0151 | Uridine Triacetate | Vistogard | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | March 1, 2016 | In Use |
Found 9,180 results in 5 milliseconds — Export these results